AusBiotech 2025 stand partners

360biolabs, a BioAgilytix company, is Australia's most comprehensive bioanalytical lab, providing a comprehensive range of assay services for the development of new therapeutics, vaccines and diagnostics in a quality-assured environment. Located in Australia, the jurisdiction of choice for early phase clinical trials, we offer a diverse range of pharmacokinetic (PK) and pharmacodynamic (PD) endpoints, including small molecule and large molecule PK, ADA, NAb, biomarkers (MSD, SIMOA, Luminex, ELISpot), molecular assays and virology, in a single laboratory for all your clinical trial requirements.

Our global BioAgilytix team, with laboratories located the United States and Germany, can support your program from discovery DMPK through to Phase 4 clinical trials. We offer seamless transfer of assays from Phase 1 in Australia to our global labs for Phase 2 support.

Our Quality Management Systems include internationally recognised accreditation (OECD GLP, GCLP, ISO/IEC17025) and our assay validation process and reporting are consistent with FDA and EMEA guidelines.

360biolabs team of highly experienced scientific and QA professionals ensures high-quality science, data integrity and regulatory compliance through all phases of clinical development. 360biolabs is a trusted partner to many top global pharmaceutical and biotech companies. Our relentless dedication to accuracy, timeliness and regulatory rigor enables your therapeutic innovations to reach patients faster.

Agilex Biolabs is Australia’s largest bioanalytical laboratory, with nearly 30 years’ experience in regulated bioanalysis. Our laboratories feature state-of-the-art equipment, including Sciex Triple Quad 6500+, MSD Quickplex 120, Cytek Aurora, BD FACSymphony A3, and droplet digital PCR, enabling comprehensive bioanalytical services. Agilex holds ISO/IEC17025 accreditation, OECD GLP recognition with NATA, and ISO27001:2022 certification for information security, ensuring the highest quality standards.

We operate from two locations, Adelaide and Brisbane, to support clinical trials across Australia. Agilex Adelaide, our headquarters, is FDA-audited and houses almost 200 staff across LC/MS, Immunoassay, and Immunobiology divisions, forming Australia’s largest bioanalytical team. Agilex Brisbane features a modern flow cytometry lab and PBMC isolation room, allowing rapid sample processing and fast data turnaround.

A global leader in flexible solutions, Agilex Biolabs has accelerated numerous pharmaceutical and biopharmaceutical drug development programs across the US, APAC, and EU, supporting diverse drug modalities and therapeutic indications with reliable, high-quality bioanalytical expertise.

CAD-IT Australia are leading experts in providing tailored digital solutions to the Australian Life Science sector. Our mission is to revolutionise Life Sciences by utilising knowledge of MedTech and Pharmaceutical industries to support digitisation and streamlining of product development and manufacturing. We partner with world leaders (PTC, Tulip, and Planeus) to provide customised digital solutions, catered to any stage of development or manufacturing. Working with CAD-IT Australia will ensure efficient, and compliant product development from ideation to realisation.

Clinials: Compliance-Built AI for Clinical Documentation and Communication Clinials is a regulated AI platform purpose-built for clinical research organisations, sites, and biotech teams. We fix one of life-science’s hardest problems: slow, error-prone, and scattered trial documentation. Clinials turns complex protocols into plain-language, audit-ready documents up to 80 % faster, automating synopses, feasibility summaries, multilingual reports, and patient materials; all within a secure, single-tenant environment that ensures compliance and traceability. Teams using Clinials cut approval cycles, eliminate rework, and communicate clearly across functions and borders. Every output is version-controlled, regionally hosted, and instantly reviewable. As AI reshapes global research, we’re proving that innovation and integrity can advance together. Clinials isn’t about replacing expertise, we give clinical teams time to focus on what matters most: the science and the patients.

Gelomics revolutionises drug development by providing a more predictive, ethical alternative to traditional cell and animal models. We enable scientists to grow functional human microtissues using our AI-powered technology, which significantly improves the accuracy of drug response predictions. This innovation reduces costs, shortens development timelines, and decreases reliance on animal testing, offering a more efficient and humane approach to pharmaceutical research.

Founded in 2015 as a Core Research Facility, Griffith University’s Clinical Trial Unit (GUCTU) is a community-focused, internationally recognised clinical trial site advancing healthcare through Phase I–IV trials. Located within the Gold Coast Health and Knowledge Precinct, and adjacent to both public and private hospitals, it benefits from a dynamic ecosystem of clinical expertise, infrastructure, and collaboration.

We offer GCP-aligned facilities and expert coordination services, supporting both academic and commercial research across a wide range of therapeutic areas - including chronic and rare diseases, vaccines, GMOs, medical devices, and complementary medicines. Our highly skilled, multidisciplinary team has upskilled students and clinicians, empowered academic researchers, and built a global client base.

Through streamlined processes, academic rigour, and strong participant engagement we drive successful project completion. To date, we have delivered over 80 commercially sponsored trials, achieving numerous Australian and global firsts in start-up timelines, enrolment numbers, and participant retention.

IntelliDesign is a design, engineering and manufacturing company based in Brisbane Australia that works with progressive organisations to create game changing technology products. We combine creative design innovation with an end-to-end capability for multidisciplinary design development, systems engineering and fully traceable electronic product manufacture.

The company has been established for more than 30 years with more than 135 staff at our two closely linked locations in Brisbane. IntelliDesign is certified to ISO13485 for medical device design and manufacture and we have been manufacturing medical devices for over 20 years, shipping 1000’s of products each month to our customers.

We have long-term partnerships with clients from the medical, industrial, mining, defence and aerospace industries. We specialise in the design and manufacturing of electronic products for technically challenging, mission critical and physically demanding environments, including medical devices and satellite technology.

Nucleus Network is a global leader in early phase clinical research, partnering with pharmaceutical and biotechnology companies to accelerate drug development with precision and reliability. With world class facilities in Australia, the United States and the United Kingdom, we form a unified global network that delivers consistent quality, speed and care across every study.

Our medical, scientific and operational teams bring more than 30 years of experience and have completed over 2,500 studies with an unwavering commitment to excellence and integrity. As the only early phase organisation operating across the three key regulatory markets of Australia, the United States and the United Kingdom, we provide unrivalled access to diverse participant populations and year round recruitment, offering end to end solutions from first in human to complex early phase designs.

Partner with Nucleus Network to advance your program with confidence, agility and global reach. Your project. Our expertise.

QIMR Berghofer is a leading force in Queensland’s health and medical research. The institute hosts 67 research laboratories and a community of more than 1,000 scientists, staff, visiting researchers, and students. With over 300 commercial contracts and 380 active patents, QIMR Berghofer is highly active in providing contract R&D services and fostering industry partnerships.

A major strength is Q-Gen Cell Therapeutics, a TGA-licensed GMP facility providing cell therapy development and manufacturing services. The institute also houses the National Centre for Spatial Tissue and AI Research (NCSTAR), offering AI-enabled, multi-modal spatial omics services to uncover treatment resistance, therapeutic vulnerabilities, novel biomarkers, and inform therapy selection.

In Q4 2025, Life Science Incubator (LSI) will launch LSI@QIMR Berghofer, Australia’s first Life Sciences Incubator, to support early-stage biotech companies and emerging therapies. The incubator will be backed by the QIMR Berghofer’s comprehensive scientific services, including several NATA-accredited facilities.

Resolian is a global Contract Research Organization (CRO) offering specialized services in GxP and non-regulated bioanalysis, DMPK, and GMP CMC analytical and materials science. With labs across the US, UK, Australia, and China, Resolian operates under a harmonised quality management system. Its team of over 500 experts supports pharmaceutical and biotech companies throughout the drug development lifecycle.

Resolian delivers advanced solutions including LC-MS/MS bioanalysis for small and large molecules, PK immunoassays, immunogenicity, biomarkers, cell-based assays, and drug metabolism studies. These services are provided through state-of-the-art laboratories tailored for both preclinical and clinical programs.

In Australia, its NATA-accredited, GLP-certified lab supports early-phase research and facilitates seamless assay transfers across its global network. Committed to quality and regulatory compliance, Resolian partners closely with clients to develop customized solutions, making it a trusted ally for companies of all sizes at any stage of drug development.

Sanofi is an R&D-driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.

Southern RNA is a leading contract development and manufacturing organisation (CDMO) of RNA-based therapeutics, committed to bringing innovative RNA-based therapies to patients as quickly as possible. The company has built a strong track record and reputation in manufacturing services for mRNA-modalities, backed by access to a supply chain of key high-quality raw-material and a world-class analytics platform dedicated to nucleic acid products. In addition to their R&D capabilities at the Gold Coast Health and Knowledge Precinct, they are set to open their small-scale, GMP mRNA manufacturing facility in early 2026, located within the Brisbane Technology Park. This significant milestone marks a readiness to support clinical trials, reinforcing a commitment to advancing the RNA-based vaccine and therapeutics sector.

Therapeutic Innovation Australia (TIA) has brought together three of its Queensland-based small molecule translational research facilities to support a vibrant pipeline of novel medicines. Our aim is to streamline enhanced and interconnected access by academic and industry groups across TIA's network of drug discovery capabilities and expertise, bridging the early stages of development. The three facilities are Compounds Australia at Griffith University’s Institute for Biomedicine and Glycomics, the Queensland Emory Drug Discovery Initiative (QEDDI), a business unit of UniQuest, and the Centre for Integrated Preclinical Drug Development (CIPDD) at the School of Biomedical Sciences at the University of Queensland. These facilities are financially supported by the Commonwealth and Queensland Governments through the National Collaborative Research Infrastructure Strategy (NCRIS) and the Research Infrastructure Co-investment Fund (RICF), respectively, with additional support from Queensland Health and host institutions.

The Translational Research Institute (TRI) in Brisbane is Australia’s leading hub for accelerating discoveries from bench to bedside. TRI unites researchers, clinicians, and industry partners to translate medicines, vaccines, diagnostics, and medical technologies into improved healthcare outcomes.

Purpose-built infrastructure supports every stage of the translational pathway—from discovery and preclinical studies through to clinical trials and commercialisation. TRI’s advanced laboratories, state-of-the-art preclinical imaging, and strong hospital and university linkages, offer a unique ecosystem where science, healthcare, and industry converge TRI is extending this capability with ENTRI, a stand-alone cGMP manufacturing facility opening in 2026. ENTRI provides licensing-ready infrastructure built to TGA and PIC/S standards, supporting tenant-led clinical manufacturing for advanced modalities under defined service and quality agreements. Its facilitator model offers flexible support in QA, validation, and logistics, without acting as a CDMO.

Together, TRI and ENTRI enable innovation to scale into real-world health impact.

Vaxxas is developing a novel technology to enhance the performance of existing and next-generation vaccines. The company believes its innovative needle-free technology, the high-density microarray patch (HD-MAP), will be fundamental to helping the world rethink what's possible with vaccines. Vaxxas' approach, which has been validated in human clinical studies can enhance the efficiency and effectiveness of a vaccine's immune response. The benefits of the technology include room temperature storage, reducing cold chain dependency; potential for improved immune response in addition to reduced needle anxiety and improved compliance - with the potential for self-administration.

Last updated: 16 Oct 2025